Posts

Vanda Pharmaceuticals Initiates Thetis Study of NEREUS™ for Preventing Vomiting in GLP-1 Receptor Agonist Users

on

Vanda Pharmaceuticals Receives FDA Approval for Bysanti (Milsaperidone) for Schizophrenia and Bipolar I Disorder

on

FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review

on

FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review

on

FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review

on

FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review

on

FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review

on

Vanda Pharmaceuticals Secures FDA Approval for NEREUS (Tradipitant), First New Motion Sickness Drug in Over 40 Years

on

Vanda Ends Lawsuits Against FDA in Broad Settlement, Paving Way for Drug Review Progress

on

Federal Appeals Court Overturns FDA Rejection of Vanda’s Hetlioz for Jet Lag Disorder

on